Providing Enhanced Capabilities for Electrophysiology Technologies—A Medtech Makers Q&A

By Sean Fenske, Editor-in-Chief

In certain situations, medical device innovation evolves rapidly. New conditions are addressed, requiring unique technologies to treat them. Under these circumstances, novel solutions are being developed and manufactured. While existing offerings can be adapted or used as a model for the new device, often a brand-new idea is the answer and must be created from the ground up.

While electrophysiology isn’t exactly new, the continued evolution of technologies under its umbrella has led to it addressing conditions in innovative ways. As a result, medical device makers offering solutions for this area require the assistance of service providers that offer specific skill sets. The broad range of capabilities needed reveals a small group of companies that can fulfill the varied requirements.

One such company, DuPont, provides such proficiencies for those seeking to develop and manufacture new electrophysiology technology. Through DuPont Healthcare Solutions and its Spectrum™ capabilities, the company supports OEMs with the expertise and end-to-end manufacturing support needed to bring new technology to market. In the following Q&A, Raghu Vadlamudi, Global Process Development Technology Leader within DuPont Healthcare Solutions, offers responses to questions about the required capabilities and how DuPont is supporting the needs of OEMs involved in this area.

Sean Fenske: What types of technologies are being leveraged for today’s electrophysiology devices? What components and services are most important for these products?

Raghu Vadlamudi: Electrophysiology (EP) devices continue to evolve rapidly as physicians look for safer, more effective treatments for cardiac arrhythmia. We are seeing strong growth in advanced mapping systems, catheter-based therapies, pulsed field ablation (PFA), radiofrequency ablation, cryoablation, and robotic-assisted navigation technologies. These systems increasingly rely on highly integrated catheter platforms that bring together mechanical, electrical, and material technologies into a single device.

From a development and manufacturing perspective, the most critical components include precision extrusions, catheter shafts, molded polymer components, machined metal components, and complex subassemblies. Just as important are the capabilities that support these products, including early-stage process development, design for manufacturability (DFM), tooling strategy, validation, automation, and transfer to commercial production. Through Spectrum™ capabilities and our broader DuPont Healthcare Solutions portfolio, we focus on aligning these elements from the beginning, helping customers build robust, scalable manufacturing processes that can consistently deliver highly complex components while meeting the stringent quality and regulatory expectations of the medical device industry.

Fenske: Where are the primary challenge points with electrophysiology devices? What aspect presents as requiring the greatest need for assistance?

Vadlamudi: The challenges largely stem from the increasing complexity and miniaturization of these devices. EP catheters often incorporate multiple materials, extremely tight tolerances, intricate assemblies, and demanding performance requirements. As these devices become more sophisticated, maintaining consistency and reproducibility at scale becomes significantly more challenging.

One of the most common needs we hear from customers is support in translating innovative device concepts into scalable, reliable manufacturing solutions. Many organizations are highly effective at advancing new technologies but need a partner that can help connect development to manufacturing in a way that holds up through clinical and commercial production. This is where early alignment becomes critical. Bringing manufacturing expertise into the process sooner allows teams to identify risks earlier, optimize designs for production, establish robust process windows, and create a more predictable path from development through commercialization.

Fenske: Does DuPont handle the electronic aspects of the electrophysiology devices? Are all aspects handled under the same roof?

Vadlamudi: DuPont brings together expertise across advanced materials, precision manufacturing, process development, molding, extrusion, machining, assembly, and packaging of medical device components and systems. Depending on the program, we can support integration activities involving electronic components, while complex electronic system design is typically led by the OEM or specialized partners. Our strength lies in providing an integrated manufacturing solution across multiple technologies.

Through the DuPont Healthcare Solutions global portfolio, we support a broad range of manufacturing capabilities, including injection molding, extrusion, precision machining, device assembly, sterile barrier packaging, and process validation. This allows customers to consolidate many critical manufacturing activities within a single quality system and development framework.

Fenske: As more companies seek the aid of contract development and manufacturing organizations (CDMOs), how does DuPont address this? Can it serve as a CDMO for electrophysiology devices?

Vadlamudi: We have a robust healthcare solutions portfolio. Through our Spectrum™ capabilities and broader manufacturing expertise, we can absolutely serve as a CDMO for the electrophysiology market and the devices it produces. The medical device industry continues to move toward strategic outsourcing, and customers increasingly seek partners that can contribute beyond traditional contract manufacturing. DuPont Healthcare Solutions is uniquely positioned to function as a development and manufacturing partner for electrophysiology programs.

Our capabilities in this market span process development, mold/die building strategy, manufacturing scale-up, validation, automation, and commercial production. More importantly, we bring deep expertise in the manufacturing technologies commonly used in EP devices, including precision extrusion, advanced injection molding, micro-manufacturing, machining, and complex device assembly. Our goal is not simply to build components but to help customers accelerate development timelines, reduce manufacturing risk, and establish scalable production platforms that support long-term growth.

Fenske: When developing electrophysiology devices, what is often overlooked or neglected to be considered? In other words, what missteps do companies make in their development? How does DuPont help with this?

Vadlamudi: One of the most common mistakes is underestimating the role of manufacturing early in development. Device designs are often optimized for clinical performance without fully considering manufacturability, process capability, inspection requirements, automation, or long-term scalability.

Another common challenge is delaying process development until later stages, when changes are more disruptive and timelines are compressed. DuPont Healthcare Solutions takes a more connected approach, where DFM and process development advance together. Our teams utilize scientific manufacturing principles and design of experiments (DOE) to establish robust manufacturing processes early in development. This approach significantly reduces risk during validation and commercialization. For customers, this early alignment leads to fewer surprises, more consistent scale-up, and a smoother path to market.

Fenske: What does DuPont see on the horizon for electrophysiology devices? Where is the growth and what is DuPont doing to prepare and respond to those needs?

Vadlamudi: The electrophysiology market is expected to see continued strong growth over the coming decade, driven by increasing prevalence of atrial fibrillation, broader adoption of minimally invasive treatments, and ongoing innovation in mapping and ablation technologies. We believe pulsed field ablation will continue to be a major growth driver, creating demand for increasingly sophisticated catheter platforms and supporting technologies. We also anticipate continued advancements in catheter miniaturization, sensing technologies, robotic navigation, and integrated diagnostic and therapeutic systems. To support these trends, DuPont Healthcare Solutions continues to advance manufacturing capabilities, process development expertise, automation, digital manufacturing tools, and micro-manufacturing technologies. We are also strengthening coordination across our global network to support customer access to the capabilities, capacity, and regional support they need as they scale.

Fenske: Do you have any additional comments you’d like to share based on any of the topics we discussed or something you’d like to tell medical device manufacturers?

Vadlamudi: The pace of innovation in electrophysiology is accelerating, but innovation alone is not enough for success. The companies that move most effectively from concept to commercialization are those that connect product development and manufacturing strategy from the very beginning. Our perspective is simple: bring the right expertise together early for the benefit of the customer and patient.

When scalability, quality, and regulatory requirements are considered alongside DFM, companies can significantly reduce development risk and accelerate time to market. Through the DuPont Healthcare Solutions portfolio, we support customers across development, scale-up, validation, and commercial manufacturing. Our objective is to help transform innovative concepts into robust, validated, and commercially successful medical devices that ultimately improve patient outcomes.

Click here to learn more about DuPont Spectrum >>>>>